Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-04-26 Annual Report
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物2021年年度报告
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed company information, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, and a full set of financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial figures, management commentary, and extensive disclosures typical of an official yearly report. Therefore, this document fits the definition of an Annual Report (10-K).
2022-04-26 Chinese
安图生物接待和推广工作及信息披露备查登记制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '郑州安图生物工程股份有限公司 接待和推广工作及信息披露备查登记制度' which translates to 'Zhengzhou Antu Bioengineering Co., Ltd. Reception and Promotion Work and Information Disclosure Filing Registration System.' It outlines the company's procedures and principles for investor relations, communication with shareholders, regulatory compliance, and information disclosure management. The content focuses on governance practices related to investor relations and information disclosure, including roles, responsibilities, communication protocols, and record-keeping. There are no financial statements, earnings data, audit opinions, or announcements of voting results. The document is a governance-related internal regulation rather than a report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-04-26 Chinese
安图生物股东大会议事规则（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '郑州安图生物工程股份有限公司 股东大会议事规则' which translates to 'Rules of Procedure for the Shareholders' General Meeting of Zhengzhou Antu Bioengineering Co., Ltd.' It details the rules, procedures, and regulations governing the convening, notification, conduct, and voting of shareholders' meetings. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is about the governance and procedural framework for shareholder meetings rather than an actual meeting presentation, voting results, or report. It is not an announcement or a report of a meeting but a governance document outlining internal rules. Therefore, it fits best under Governance Information (CGR). The document length (7863 characters) and detailed procedural content support this classification with high confidence.
2022-04-26 Chinese
安图生物关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association (公司章程). It includes specific changes to various articles, governance rules, board and shareholder meeting procedures, and rights and obligations of directors, supervisors, and senior management. The document is issued by the company's board and is a formal announcement of these governance changes. It does not contain financial statements, audit opinions, or financial results. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is a governance-related announcement about internal company rules and structure. Therefore, the document fits best under the category of Governance Information (CGR). The document length is over 10,000 characters, indicating it is a full document, not a brief announcement or notice of publication.
2022-04-26 Chinese
安图生物2021年度募集资金存放和实际使用专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021年度募集资金存放和实际使用专项报告" which translates to "2021 Annual Report on the Storage and Actual Use of Raised Funds." It details the management, storage, and usage of funds raised through convertible bonds and private stock issuance, including specific amounts, usage, and regulatory compliance. It references regulatory guidelines related to the management and use of raised funds, includes detailed financial tables on fund usage, and contains audit and sponsor institution verification reports. The document is comprehensive and focused on the specific topic of raised funds usage and management for the year 2021, not a general annual report or earnings release. This type of report corresponds to a specialized report on capital raising and fund usage, which aligns with the category "Capital/Financing Update (CAP)" as it provides updates on company fundraising and capital usage. The document length is substantial (15,000 characters), and it contains detailed financial data and regulatory compliance information, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-04-26 Chinese
招商证券关于安图生物2021年持续督导年度报告书
Regulatory Filings
2022-04-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.